loading
前日終値:
$4.02
開ける:
$4.07
24時間の取引高:
9,328
Relative Volume:
0.09
時価総額:
$225.94M
収益:
-
当期純損益:
$-66.86M
株価収益率:
-3.3458
EPS:
-1.2
ネットキャッシュフロー:
$-58.82M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+5.80%
6か月 パフォーマンス:
-20.75%
1年 パフォーマンス:
-2.20%
1日の値動き範囲:
Value
$3.945
$4.07
1週間の範囲:
Value
$3.8375
$4.34
52週間の値動き範囲:
Value
$2.60
$7.77

Design Therapeutics Inc Stock (DSGN) Company Profile

Name
名前
Design Therapeutics Inc
Name
セクター
Healthcare (1171)
Name
電話
858-293-4900
Name
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
Name
職員
56
Name
Twitter
Name
次回の収益日
2025-03-10
Name
最新のSEC提出書
Name
DSGN's Discussions on Twitter

DSGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
DSGN
Design Therapeutics Inc
3.98 229.35M 0 -66.86M -58.82M -1.20
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.21 123.14B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
546.06 60.43B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.00 42.07B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
572.21 34.47B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.13 27.42B 3.81B -644.79M -669.77M -6.24

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-07 アップグレード Piper Sandler Neutral → Overweight
2023-11-14 ダウングレード Piper Sandler Overweight → Neutral
2023-08-15 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-08-15 ダウングレード SVB Securities Outperform → Market Perform
2023-08-15 ダウングレード Wedbush Outperform → Neutral
2023-05-04 アップグレード Goldman Sell → Neutral
2022-06-10 開始されました Wedbush Outperform
2022-05-02 開始されました RBC Capital Mkts Outperform
2022-01-19 開始されました Goldman Sell
2021-04-20 開始されました Goldman Neutral
2021-04-20 開始されました Piper Sandler Overweight
2021-04-20 開始されました SVB Leerink Outperform
すべてを表示

Design Therapeutics Inc (DSGN) 最新ニュース

pulisher
06:29 AM

Design Therapeutics (NASDAQ:DSGN) Stock Price Down 3.1% – Should You Sell? - Defense World

06:29 AM
pulisher
02:50 AM

What analysts say about Design Therapeutics Inc. stockTriple returns potential - Jammu Links News

02:50 AM
pulisher
02:31 AM

Is Design Therapeutics Inc. stock a growth or value playFree Stock Market Forecasting Tools - newser.com

02:31 AM
pulisher
Jul 16, 2025

Why Design Therapeutics Inc. stock attracts strong analyst attentionDefensive Stock Picks with Upside - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

Why Synaptogenix Inc. stock attracts strong analyst attentionSecure Your Capital Strategy - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Design Therapeutics Inc. stock price move sharplyDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Sionna Therapeutics Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Design Therapeutics Inc. stock performs during market volatilityElite Stock Shortlist - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Penny Stocks To Watch In July 2025 - simplywall.st

Jul 10, 2025
pulisher
Jul 10, 2025

Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest

Jul 10, 2025
pulisher
Jun 26, 2025

BioVie Highlights Patient-Centric Design of SUNRISE-PD - GlobeNewswire

Jun 26, 2025
pulisher
Jun 17, 2025

FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer - Stock Titan

Jun 17, 2025
pulisher
Jun 12, 2025

Design Therapeutics Confirms Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Design Therapeutics reports voting results from annual meeting - Investing.com

Jun 12, 2025
pulisher
Jun 07, 2025

Squarepoint Ops LLC Has $297,000 Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - The Malaysian Reserve

Jun 05, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Sells 54,550 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Design Therapeutics starts Friedreich ataxia patient trial By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : Design Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

RBC Capital maintains Design Therapeutics stock rating with $5 target - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics (DSGN) Advances Friedreich Ataxia Clinical T - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics starts Friedreich ataxia patient trial - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND Application - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Sells 556,157 Shares of Aegon Ltd. (NYSE:AEG) - Defense World

Jun 04, 2025
pulisher
May 29, 2025

40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World

May 29, 2025
pulisher
May 28, 2025

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - TradingView

May 28, 2025
pulisher
May 28, 2025

Clinical-Stage Biotech Design Therapeutics Set for Major Jefferies Healthcare Conference Presentation - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Autodesk (NASDAQ:ADSK) Price Target Raised to $376.00 at Citigroup - Defense World

May 28, 2025
pulisher
May 27, 2025

Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com

May 27, 2025
pulisher
May 27, 2025

As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail

May 27, 2025
pulisher
May 25, 2025

Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 25, 2025
pulisher
May 22, 2025

3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance

May 22, 2025
pulisher
May 20, 2025

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News

May 20, 2025
pulisher
May 20, 2025

Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire

May 20, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 19, 2025
pulisher
May 16, 2025

Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World

May 16, 2025

Design Therapeutics Inc (DSGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.19
price up icon 0.86%
$35.45
price up icon 0.37%
$104.57
price up icon 0.51%
$27.95
price up icon 1.07%
$110.73
price down icon 0.10%
biotechnology ONC
$298.88
price up icon 3.15%
大文字化:     |  ボリューム (24 時間):